Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treating generalized anxiety disorder.

Jack M Gorman1

  • 1Department of Psychiatry, Mt. Sinai School of Medicine, New York, NY 10029, USA.

The Journal of Clinical Psychiatry
|March 11, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

'They've all endorsed it…but I'm just not there:' a qualitative exploration of COVID-19 vaccine hesitancy reported by Black and Latinx individuals.

BMJ open·2023
Same author

Community-oriented Motivational Interviewing (MI): A novel framework extending MI to address COVID-19 vaccine misinformation in online social media platforms.

Computers in human behavior·2022
Same author

Improving maternal mental health: assessing the extent of screening and training about peripartum depression.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·2022
Same author

Agreement in patient-therapist alliance ratings and its relation to dropout and outcome in a large sample of cognitive behavioral therapy for panic disorder.

Psychotherapy research : journal of the Society for Psychotherapy Research·2022
Same author

Corrigendum: Implications of COVID-19 Vaccine Hesitancy: Results of Online Bulletin Board Interviews.

Frontiers in public health·2022
Same author

Implications of COVID-19 Vaccine Hesitancy: Results of Online Bulletin Board Interviews.

Frontiers in public health·2022
Same journal

Major Depressive Disorder and PTSD Treatment Outcome in Interpersonal Psychotherapy and Prolonged Exposure.

The Journal of clinical psychiatry·2026
Same journal

Psychiatrists and Medical Aid in Dying: Entering Uncharted Waters.

The Journal of clinical psychiatry·2026
Same journal

Mind and Metabolism in Crisis: US Mortality Involving Obesity and Psychiatric Disorders-Trends, Disparities, and ARIMA Projections.

The Journal of clinical psychiatry·2026
Same journal

Generative AI for the Clinical Psychopharmacologist: Is It Ready for Prime Time?

The Journal of clinical psychiatry·2026
Same journal

Posttrauma Benzodiazepine Use and Subsequent PTSD: A Population-Wide Analysis Following Extreme Traumatic Exposure.

The Journal of clinical psychiatry·2026
Same journal

The Challenges of PTSD Prevention: Placing Benzodiazepine Use in Context.

The Journal of clinical psychiatry·2026
See all related articles

Generalized anxiety disorder (GAD) requires long-term treatment. Antidepressants like venlafaxine and paroxetine are effective for GAD and comorbid depression, offering a better long-term solution than benzodiazepines.

Area of Science:

  • Psychiatry
  • Clinical Psychology
  • Pharmacology

Background:

  • Generalized anxiety disorder (GAD) is marked by persistent worry, necessitating effective long-term management strategies.
  • Comorbid depression frequently accompanies GAD, complicating treatment selection.
  • Existing treatments vary in efficacy and suitability for long-term GAD management.

Purpose of the Study:

  • To review the benefits and risks of pharmacologic and psychological therapies for GAD.
  • To assess the efficacy of treatments in eliminating GAD symptoms and restoring function.
  • To identify optimal long-term treatment options for GAD, considering comorbid conditions.

Main Methods:

  • Literature review of pharmacologic and psychotherapeutic interventions for GAD.

Related Experiment Videos

  • Comparative analysis of treatment efficacy, side-effect profiles, and long-term outcomes.
  • Evaluation of treatments for GAD with comorbid depression.

    • Main Results:

    • Psychotherapies (applied relaxation, cognitive therapy, cognitive-behavioral therapy) are effective as monotherapies or adjuncts.
    • Pharmacotherapies include benzodiazepines, buspirone, venlafaxine, and paroxetine.
    • Benzodiazepines are suitable for short-term use but have side effects and no antidepressant action.
    • Buspirone has anxiolytic effects but limited antidepressant action.
    • Venlafaxine and paroxetine are effective anxiolytics and antidepressants, suitable for long-term GAD treatment with comorbid depression.

    Conclusions:

    • Antidepressants, specifically venlafaxine and paroxetine, demonstrate significant efficacy for long-term GAD treatment.
    • These antidepressants are particularly valuable for patients with co-occurring depression.
    • Psychological therapies offer effective alternatives or adjuncts to pharmacotherapy for GAD management.